After Moderna's 672% Climb, The Story Has Changed

Moderna spent much of 2025 caught between bullish hopes for mRNA expansion and bearish warnings about shrinking COVID demand and tighter pricing. For Moderna shareholders, the return over the past year was 671.9%, including dividends. If you had been weighing those sharply different analyst views in October 2025, how would you have judged the odds that such an extreme outcome could follow from the business that was on record then? The move put Moderna in the middle of this trade. Scan 36...